Neuren Pharmaceuticals (ASX:NEU) Presentation, FNN Investor Event, March 2019, Sydney

Company Presentations

Neuren Pharmaceuticals Limited (ASX:NEU) Executive Chairman, Dr Richard Treagus presents on strategy and outlook, provides an update on the company's partnership with ACADIA Pharmaceuticals (NASDAQ:ACAD) and the upcoming Phase 3 trial of its lead drug candidate Trofinetide for the treatment of Rett Syndrome, and discusses further partnering opportunities in Europe and Japan at FNN's Investor Event.

Key points:


  • A biopharmaceutical company developing new therapies for neurodevelopmental disorders
  • Testing efficacy of 2 drugs in multiple debilitating childhood disorders
  • Strong support from advocacy groups and leading physicians
  • High value partnering deal with ACADIA Pharmaceuticals for North America
  • ACADIA committed to invest $77 million in Rett Syndrome Phase 3 trial starting in 2019
  • Provides development and commercialisation capabilities for Trofinetide in the US
  • Neuren seeking partners to commercialise outside North America
For more, watch Executive Chairman Dr Richard Treagus present.